Evidence of transfusion‐induced reductions in cerebral capillary shunting in sickle cell disease
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25863
Abstract: 2016;30(2):268-273. 5. Lamba J, Chauhan L, Shin M, et al. CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial. Blood. 2017;130(suppl 1): 3826.… read more here.
Keywords: induced reductions; cd33; reductions cerebral; transfusion induced ... See more keywords
CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of cancer"
DOI: 10.1002/ijc.33865
Abstract: Immunotherapies, such as chimeric antigen receptor (CAR) modified T cells and antibody-drug conjugates (ADCs), have revolutionized the treatment of cancer, especially of lymphoid malignancies. The application of targeted immunotherapy to patients with acute myeloid leukemia… read more here.
Keywords: cd33; generation; stem; leukemia ... See more keywords
Controversies about the subcellular localization and mechanisms of action of the Alzheimer's disease-protective CD33 splice variant
Sign Up to like & getrecommendations! Published in 2019 at "Acta Neuropathologica"
DOI: 10.1007/s00401-019-02065-1
Abstract: Genome-wide association studies (GWAS) identified an allele of the microglial CD33 (Siglec-3) cell surface receptor that protects against Alzheimer’s disease (AD). Protected individuals express less full-length CD33 and more alternatively spliced D2-CD33 lacking the amino-terminal… read more here.
Keywords: cd33; alzheimer disease; localization; cell surface ... See more keywords
Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Experimental hematology"
DOI: 10.1016/j.exphem.2017.06.007
Abstract: Acute myeloid leukemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure. AML is a clinically, morphologically, and genetically heterogeneous disease, and biological differences… read more here.
Keywords: cd33; adult childhood; acute myeloid; myeloid ... See more keywords
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Sign Up to like & getrecommendations! Published in 2021 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2021.10.007
Abstract: BACKGROUND AIMS Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia-associated antigen with chimeric antigen receptor (CAR) T cells have met with limited success, due in part to heterogeneous… read more here.
Keywords: cll; antigen; cd33; myeloid ... See more keywords
Common determinants of severe Covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related Siglecs, Siglec-3 and Siglec-5/14
Sign Up to like & getrecommendations! Published in 2020 at "Medical Hypotheses"
DOI: 10.1016/j.mehy.2020.110168
Abstract: Abstract SARS-CoV-2 interaction with the ACE-2 receptor cannot alone explain the demography and remarkable variation in clinical progression of Covid-19 infection. Unlike SARS-CoV, the cause of SARS, several SARS-CoV-2 spike glycans contain sialic acid residues.… read more here.
Keywords: siglec; cd33; severe covid; sars cov ... See more keywords
Discovery of Small-Molecule CD33 Pre-mRNA Splicing Modulators.
Sign Up to like & getrecommendations! Published in 2022 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.1c00396
Abstract: CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. Multiple genome-wide association studies (GWAS) have identified genetic variants in the CD33 gene that convey protection from late-onset Alzheimer's… read more here.
Keywords: cd33 pre; pre mrna; cd33; mrna ... See more keywords
CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Sign Up to like & getrecommendations! Published in 2018 at "Human gene therapy"
DOI: 10.1089/hum.2017.241
Abstract: Acute myeloid leukemia (AML) is a kind of a malignant hematologic tumor caused by uncontrolled repopulation of myeloid hematopoietic stem cells (HSCs). Current therapeutic effects for AML patients are unsatisfactory. In particular, relapsed and refractory… read more here.
Keywords: cd33; antigen; car cells; aml ... See more keywords
Midostaurin abrogates CD33‐directed UniCAR and CD33‐CD3 bispecific antibody therapy in acute myeloid leukaemia
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15975
Abstract: Combinatory therapeutic approaches of different targeted therapies in acute myeloid leukaemia are currently under preclinical/early clinical investigation. To enhance anti‐tumour effects, we combined the tyrosine kinase inhibitor (TKI) midostaurin and T‐cell mediated immunotherapy directed against… read more here.
Keywords: cd33; cell; myeloid leukaemia; acute myeloid ... See more keywords
SRSF1 and PTBP1 Are trans-Acting Factors That Suppress the Formation of a CD33 Splicing Isoform Linked to Alzheimer’s Disease Risk
Sign Up to like & getrecommendations! Published in 2019 at "Molecular and Cellular Biology"
DOI: 10.1128/mcb.00568-18
Abstract: A single nucleotide polymorphism (SNP) in exon 2 of the CD33 gene is associated with reduced susceptibility to late-onset Alzheimer’s disease (AD) and causal for elevated mRNA lacking exon 2. In contrast to full-length CD33,… read more here.
Keywords: exon; lacking exon; alzheimer disease; cd33 ... See more keywords
IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-17-1077
Abstract: The myeloid differentiation antigen CD33 has long been exploited as a target for antibody-based therapeutic approaches in acute myeloid leukemia (AML). Validation of this strategy was provided with the approval of the CD33-targeting antibody–drug conjugate… read more here.
Keywords: cd33 targeting; cd33; targeting antibody; aml ... See more keywords